A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

Summary

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.

Eligibility

Age range

Not specified

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Daratumumab

  Daratumumab will be administered either intravenously or subcutaneously.

• Drug
  Carfilzomib

  Carfilzomib will be administered intravenously.

• Drug
  Dexamethasone

  Dexamethasone will be administered either orally or intravenously.

• Drug
  Lenalidomide

  Lenalidomide will be administered orally.

• Drug
  Pomalidomide

  Pomalidomide will be administered orally.

Locations (91)